1. Home
  2. PKG vs UTHR Comparison

PKG vs UTHR Comparison

Compare PKG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Packaging Corporation of America

PKG

Packaging Corporation of America

HOLD

Current Price

$207.34

Market Cap

17.4B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$579.80

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKG
UTHR
Founded
1867
1996
Country
United States
United States
Employees
13600
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.4B
25.1B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
PKG
UTHR
Price
$207.34
$579.80
Analyst Decision
Buy
Buy
Analyst Count
8
14
Target Price
$232.50
$567.57
AVG Volume (30 Days)
752.9K
551.7K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
2.42%
N/A
EPS Growth
N/A
13.07
EPS
8.58
27.86
Revenue
$8,989,300,000.00
$1,483,300,000.00
Revenue This Year
$14.44
$7.08
Revenue Next Year
$4.07
$14.32
P/E Ratio
$24.08
$20.75
Revenue Growth
7.23
2.38
52 Week Low
$176.45
$272.18
52 Week High
$249.51
$607.89

Technical Indicators

Market Signals
Indicator
PKG
UTHR
Relative Strength Index (RSI) 43.41 61.58
Support Level $201.83 $464.92
Resistance Level $216.77 $607.89
Average True Range (ATR) 4.50 16.87
MACD 0.60 -0.45
Stochastic Oscillator 40.50 67.68

Price Performance

Historical Comparison
PKG
UTHR

About PKG Packaging Corporation of America

Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: